Abstract
BackgroundHepatocellular carcinoma (HCC) is a common human malignant cancer due to a high metastatic capacity and the recurrence rate is also high. This study is aim to investigate the role of musashi1 as a potential biomarker for therapy of HCC.MethodsThe mRNA and protein expression levels of musashi1 were detected in HCC samples and cell lines. The malignant properties of HCC cells, including proliferation, invasion and migration were measured by overexpressing or knocking down expression of musashi1. Additionally, the correlation between musashi1 and clinicopathological indexes and prognosis were analyzed. The expression of CD44 was measured and the correlation between CD44 and musashi1 was analyzed.ResultsIn vitro cytological experiments demonstrated that musashi1 was elevated in HCC samples and cell lines and this increased expression affected cancer cell viability, migration and invasive capacity by activating of the Wnt/β-catenin signaling pathway. Analysis of clinicopathological characteristics suggested that up-regulation of musashi1 was related to metastasis potential and a poor prognosis. Besides, there was a positive correlation between CD44 and musashi1 expression. Upregulation of musashi1 in malignant liver tumors may have contributed to the maintenance of stem-cell like characteristics of HCC cells.ConclusionsUpregulation of musashi1 could enhance malignant development of HCC cells and thus might be a novel marker for HCC therapy.
Highlights
Hepatocellular carcinoma (HCC) is a common human malignant cancer due to a high metastatic capacity and the recurrence rate is high
The expression of musashi1 was significantly higher in 57 HCC cases (56/67, 83.6%; Fig. 1a). 30 cases of HCC tissues and adjacent normal liver tissues were selected for analysis of musashi1 mRNA and protein expression
Our results found that both mRNA and protein expression of musashi1 were significantly upregulated in HCC tissues (Fig. 1b and c; P
Summary
Hepatocellular carcinoma (HCC) is a common human malignant cancer due to a high metastatic capacity and the recurrence rate is high. Hepatocellular carcinoma (HCC) accounts for 70–85% of cases of PLC based on histological classification [3]. Several improvements have been made in the diagnosis and treatment of HCC in recent decades, the high recurrence and metastatic rate seriously reduces prognosis [4]. Examining the mechanisms underlying recurrence and metastasis may assist in limiting tumor malignant progression, improve the prognosis and survival of patients. The specific molecular mechanisms underlying HCC malignant development still unknown. Devepment of new valuble targets may provide potential targets for preventing HCC invasion and metastasis
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
